Are you interested in becoming a commercial Unmanned Aerial Vehicle (UAV) remote pilot or are already flying without the Federal Aviation Administration (FAA) certification but would like to obtain your license?

Current Weather

Right Now
45°
Sunny
  • Humidity: 43%
  • Cloud Coverage:3%
  • Wind: 5 mph
  • UV Index: 4 Moderate
  • Sunrise: 06:18 AM
  • Sunset: 05:47:18 PM

Today

Sunny. High 47F. Winds NNW at 5 to 10 mph.

Tonight

Clear to partly cloudy. Low 26F. Winds NNE at 5 to 10 mph.

Tomorrow

Some clouds in the morning will give way to mainly sunny skies for the afternoon. High 48F. Winds N at 5 to 10 mph.

Recent Obituaries

Follow us on Facebook





featured

When Covington hosted Terre Haute North on Friday night, it was the second time the 1A Trojans had faced a 4A school in boys’ basketball this season.

Throughout the past year, the Indianapolis Star has published a fine series of 11 major stories plus several follow-up and daily stories detailing the unsavory business practices of Indiana’s nursing facilities and the poor care delivered by many of them.

Trending Food Videos

  • Updated

INDIANAPOLIS, March 5, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP scientific opinion under Article 5.3 of regulation 726/2004 provides a harmonized, EU-level opinion on the efficacy, quality, and safety of the antibodies. The opinion can now be considered by the EU member states when making decisions on the use of the therapies at a national level before a formal marketing authorization is issued.

  • Updated

INDIANAPOLIS, March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial in relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other non-Hodgkin's lymphomas. Pirtobrutinib is an investigational, highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor.